source
- J&J strikes up to $925M deal with Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson announced a collaboration with Flagship Pioneering’s Sail Biomedicines to develop in vivo CAR‑T therapies for immune‑mediated diseases. The agreement provides up to $925 million i…
- Biopharma layoffs in 2026 often marred by impersonal and poorly timed communicationsOver 50 biopharma companies have announced workforce cuts or plan to do so in 2026. According to a BioSpace survey, the manner in which these layoffs are communicated can leave a lasting negative i…